As bankers predict a rise in private equity exits this year, one of 2024’s M&A moves could come from the drug manufacturing realm.
Investment giant Bain Capital is weighing a potential sale of its Dutch antibiotics and active pharmaceutical ingredients (API) specialist Centrient Pharmaceuticals, which could be valued as high as €1 billion ($1.09 billion), Bloomberg reported Wednesday, citing people close to the talks.
